Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multicenter extension study for patients previously enrolled in Genentech/Roche-sponsored studies
CTR20251493Phase 3Active
- Sponsor
- Roche
- Start
- May 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tiragolumab in small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), esophageal cancer, gastric cancer (GC), esophagogastric junction cancer, sponsored by Roche. Started May 2025; status: active.
02
Drugs
tiragolumab
03
Conditions
small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)esophageal cancergastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on CTR20251493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251493.